Developing 3D Organized Human Cardiac Tissue within a Microfluidic Platform
June 15th, 2021
4.7K views
The goal of this protocol is to explain and demonstrate the development of a three-dimensional (3D) microfluidic model of highly aligned human cardiac tissue, composed of stem cell-derived cardiomyocytes co-cultured with cardiac fibroblasts (CFs) within a biomimetic, collagen-based hydrogel, for applications in cardiac tissue engineering, drug screening, and disease modeling.
Overview
This article presents a detailed protocol for engineering a 3D mature human cardiac tissue using stem cell-derived cardiomyocytes (CMs) within a microfluidic device. The method emphasizes the creation of an anisotropic cardiac tissue-on-a-chip model that closely mimics the structural and cellular complexity of native myocardium, addressing key challenges in cardiac tissue modeling for research and pharmaceutical testing.
Key Study Components
Area of Science
- Cardiac tissue engineering
- Stem cell biology
- Microfluidics
- In vitro disease modeling
Background
- Cardiovascular disease is the leading cause of death globally.
- Traditional in vitro cardiac models lack the 3D anisotropy and cellular complexity of the myocardium.
- Obtaining adult human cardiomyocytes is limited by ethical and practical constraints.
- Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly used for cardiac tissue modeling.
Purpose of Study
- To develop a protocol for generating 3D mature human cardiac tissue from hiPSC-CMs within a microfluidic device.
- To replicate the anisotropic architecture and cellular composition of native myocardium in vitro.
- To provide a platform suitable for fundamental biology studies, disease modeling, and drug screening.
Methods Used
- Isolation and dissociation of human cardiac fibroblasts and hiPSC-derived cardiomyocytes.
- Purification and counting of cells using hemocytometry and centrifugation.
- Preparation of a collagen-based hydrogel for cell encapsulation.
- Co-culture of CMs and cardiac fibroblasts in defined ratios within the hydrogel.
- Injection of the cell-laden hydrogel into a microfluidic device with elliptical microposts to induce tissue alignment.
- Culture and maintenance of the engineered tissue for up to 14 days, with periodic imaging and analysis.
Main Results
- Successful formation of highly aligned 3D cardiac tissue structures around microposts after 14 days in culture.
- Observation of spontaneous contractions in engineered tissues at day 14.
- Immunofluorescent staining revealed aligned actin fibers, mature sarcomeres, and localized gap junctions.
- The protocol enables reproducible generation of anisotropic cardiac tissue mimicking native myocardium.
Conclusions
- The described protocol allows for the creation of 3D mature human cardiac tissue with structural and functional properties similar to native heart muscle.
- This tissue-on-a-chip model is valuable for basic research, disease modeling, and pharmaceutical testing.
- Careful handling of microfluidic devices and temperature control during hydrogel injection are critical for success.
Frequently Asked Questions
What is the main advantage of using a microfluidic device with elliptical microposts in this protocol?
The elliptical microposts induce high degrees of alignment in the encapsulated cardiac cells and hydrogel matrix, closely mimicking the anisotropic architecture of native myocardium.
Why are hiPSC-derived cardiomyocytes used instead of primary adult human cardiomyocytes?
Primary adult human cardiomyocytes are difficult to obtain due to ethical and practical limitations, while hiPSC-derived CMs are more accessible and can be differentiated in vitro for tissue engineering.
How is cell viability and distribution ensured during hydrogel encapsulation?
Cells are carefully counted, resuspended to desired concentrations, and mixed thoroughly with the collagen hydrogel on ice to ensure homogeneous distribution and prevent premature polymerization.
What are the critical steps for successful tissue formation in this protocol?
Key steps include maintaining low temperatures during hydrogel preparation and injection, steady and complete filling of the microfluidic channel, and careful handling of devices to avoid premature polymerization or drying.
How is tissue maturation and alignment assessed in the engineered cardiac tissue?
After 14 days of culture, tissue maturation is evaluated by observing spontaneous contractions and performing immunofluorescent staining for actin fibers, sarcomeres, and gap junctions.
What applications are envisioned for this 3D cardiac tissue-on-a-chip model?
The model is suitable for fundamental cardiac biology studies, disease modeling, and pharmaceutical drug screening due to its physiological relevance and reproducibility.
What precautions should be taken during the protocol?
All materials should be kept on ice during hydrogel injection, and microfluidic devices should be handled gently throughout fabrication, injection, and culture to ensure tissue integrity.
Executive Industry Relevance
Engineering 3D organized human cardiac tissue within a microfluidic platform addresses the critical gap in physiologically relevant in vitro cardiac models for drug discovery and disease research. This approach enables predictive evaluation of cardiac function and tissue architecture, supporting translational continuity from early discovery through preclinical assessment. The platform's reproducibility and alignment with native myocardium architecture enhance confidence in mechanistic and safety studies across the biopharma pipeline.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of cardiac-specific pathways in a structurally relevant human tissue context.
- Supports biological de-risking by modeling native myocardium anisotropy and cellular complexity.
- Facilitates functional target validation through observation of tissue maturation and contractility.
Screening & Assay Development
- Provides a standardized 3D cardiac tissue system for reproducible compound screening.
- Delivers quantitative outputs such as tissue alignment, contraction, and marker expression.
- Enables scalability and platform reuse for high-content screening applications.
Translational & Preclinical Research
- Aligns with disease-relevant human cardiac biology for translational biomarker studies.
- Supports continuity from discovery to preclinical validation by modeling human tissue responses.
- Reduces risk of late-stage attrition by providing predictive human cardiac data.
Pipeline & Workflow Integration
This microfluidic 3D cardiac tissue model integrates into the discovery-to-preclinical continuum, enabling hypothesis testing, assay development, and translational research within a single platform.
- Discovery Biology: Supports mechanistic studies and pathway clarification in a human-relevant system.
- Screening: Offers reproducible, quantitative readouts for compound evaluation and safety profiling.
- Analytics: Provides measurable outputs such as tissue alignment, contractility, and marker localization for comparative analysis.
- Translational Research: Bridges in vitro findings to preclinical models by mimicking native cardiac tissue architecture.
- Enterprise Reuse: Establishes a reusable platform for ongoing cardiac biology and pharmacology studies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac research.
- Operational Value: Standardizes tissue engineering and assay workflows for reproducibility and scalability.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by providing robust human cardiac data early in development.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of cardiac-targeted assets.
Implementation Considerations
- Requires expertise in stem cell biology, tissue engineering, and microfluidics.
- Demands access to specialized microfluidic devices and imaging infrastructure.
- Necessitates cross-team standardization for reproducible tissue formation and analysis.
- Adaptation may be needed for different cardiac cell sources or disease models.
- Careful temperature and handling protocols are critical to prevent premature hydrogel polymerization and ensure tissue integrity.
Biopharma FAQs
Why is null hypothesis testing important for 3D cardiac tissue target validation?
Null hypothesis testing in this 3D cardiac tissue model enables objective assessment of whether observed functional or structural changes are due to specific interventions, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation in microfluidic cardiac tissue models fit the discovery pipeline?
Isolating variables such as cell type ratios or compound exposure within the microfluidic platform allows precise attribution of effects, streamlining mechanistic studies and supporting confident progression through the discovery pipeline.
What do quantitative measurements of tissue alignment and contraction enable in cardiac assays?
Quantitative readouts of tissue alignment and spontaneous contraction provide actionable data for comparing experimental conditions, informing compound selection, and supporting translational relevance in cardiac safety and efficacy studies.
Why do replication requirements matter for cross-functional cardiac tissue research?
Replication ensures that engineered tissue responses are consistent and reproducible across teams, facilitating reliable data sharing and collaborative decision-making in multi-disciplinary R&D environments.
What statistical analysis capabilities are required before implementing 3D cardiac tissue screening?
Robust statistical analysis of tissue morphology, contractility, and marker expression is essential to validate assay performance, establish thresholds for biological significance, and support data-driven advancement decisions in the pipeline.
